These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 14274828)

  • 41. Synthesis and xanthine oxidase inhibitory activity of 7-methyl-2-(phenoxymethyl)-5H-[1,3,4]thiadiazolo[3,2-a]pyrimidin-5-one derivatives.
    Sathisha KR; Khanum SA; Chandra JN; Ayisha F; Balaji S; Marathe GK; Gopal S; Rangappa KS
    Bioorg Med Chem; 2011 Jan; 19(1):211-20. PubMed ID: 21163661
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Current biochemical acquisitions on pathogenesis of gout].
    Marcolongo R
    Reumatismo; 1971; 23(3):109-25. PubMed ID: 5150688
    [No Abstract]   [Full Text] [Related]  

  • 43. Genomic sequencing of uric acid metabolizing and clearing genes in relationship to xanthine oxidase inhibitor dose.
    Carroll MB; Smith DM; Shaak TL
    Rheumatol Int; 2017 Mar; 37(3):445-453. PubMed ID: 27798726
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Xanthine oxidoreductase and its inhibitors: relevance for gout.
    Day RO; Kamel B; Kannangara DR; Williams KM; Graham GG
    Clin Sci (Lond); 2016 Dec; 130(23):2167-2180. PubMed ID: 27798228
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Treatment of gout by reduction of uric acid production.
    Kersley GD
    Ann Rheum Dis; 1966 Jul; 25(4):353-5. PubMed ID: 5947580
    [No Abstract]   [Full Text] [Related]  

  • 46. Pharmacologic approach to the maintenance of urate homeostasis.
    Kelley WN
    Nephron; 1975; 14(1):99-115. PubMed ID: 1091870
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [URIC ACID METABOLISM AND SALIDIURETICS].
    REUTTER F; SCHAUB F
    Dtsch Med Wochenschr; 1964 Jun; 89():1101-4. PubMed ID: 14152365
    [No Abstract]   [Full Text] [Related]  

  • 48. Allopurinol: alteration in pyrimidine metabolism in man.
    Kelley WN; Beardmore TD
    Science; 1970 Jul; 169(3943):388-90. PubMed ID: 5450375
    [TBL] [Abstract][Full Text] [Related]  

  • 49. XANTHINE AS A PRECURSOR OF NUCLEIC ACID PURINES IN THE MOUSE.
    POMALES R; ELION GB; HITCHINGS GH
    Biochim Biophys Acta; 1965 Mar; 95():505-6. PubMed ID: 14342542
    [No Abstract]   [Full Text] [Related]  

  • 50. Irreversible enzyme inhibitors. XCII. Inhibition of xanthine oxidase by some purines and pyrimidines.
    Baker BR; Hendrickson JL
    J Pharm Sci; 1967 Aug; 56(8):955-9. PubMed ID: 6035343
    [No Abstract]   [Full Text] [Related]  

  • 51. [DISEASES OF THE METABOLISM OF PURINES AND PYRIMIDINES].
    FRANCOMANERA R
    Rev Clin Esp; 1963 Aug; 90():203-16. PubMed ID: 14091043
    [No Abstract]   [Full Text] [Related]  

  • 52. An allopurinol-controlled, randomized, double-dummy, double-blind, parallel between-group, comparative study of febuxostat (TMX-67), a non-purine-selective inhibitor of xanthine oxidase, in patients with hyperuricemia including those with gout in Japan: phase 3 clinical study.
    Kamatani N; Fujimori S; Hada T; Hosoya T; Kohri K; Nakamura T; Ueda T; Yamamoto T; Yamanaka H; Matsuzawa Y
    J Clin Rheumatol; 2011 Jun; 17(4 Suppl 2):S13-8. PubMed ID: 21654265
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Biochemical effectiveness of allopurinol and allopurinol-probenecid in previously benzbromarone-treated gout patients.
    Reinders MK; van Roon EN; Houtman PM; Brouwers JR; Jansen TL
    Clin Rheumatol; 2007 Sep; 26(9):1459-65. PubMed ID: 17308859
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Recent advances in management of gout.
    Suresh E; Das P
    QJM; 2012 May; 105(5):407-17. PubMed ID: 22198943
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Approach to the treatment of hyperuricemia.
    Poon SH; Hall HA; Zimmermann B
    Med Health R I; 2009 Nov; 92(11):359-62. PubMed ID: 19999894
    [No Abstract]   [Full Text] [Related]  

  • 56. [Maintenance therapy of gout].
    Hart FD
    Clin Ter; 1967 Mar; 40(6):511-9. PubMed ID: 5601192
    [No Abstract]   [Full Text] [Related]  

  • 57. [Our experience in the treatment of hyperuricemia with a xanthine oxidase inhibitor (HPP), Allopurinol].
    Rapado Errazti A
    Rev Esp Reum Enferm Osteoartic; 1966 Oct; 11(8):304-6. PubMed ID: 5997999
    [No Abstract]   [Full Text] [Related]  

  • 58. [CORTICOSTEROID THERAPY OF GOUT].
    ROBECCHI A
    Minerva Med; 1964 Oct; 55():3269-76. PubMed ID: 14225464
    [No Abstract]   [Full Text] [Related]  

  • 59. Drugs for gout.
    Med Lett Drugs Ther; 2014 Mar; 56(1438):22-4. PubMed ID: 24791281
    [No Abstract]   [Full Text] [Related]  

  • 60. Allopurinol in the prevention of hyperuricaemia secondary to the treatment of neoplastic diseases with alkylating agents, adrenal steroids, and radiation therapy.
    Krakoff IH; Balis ME
    Ann Rheum Dis; 1966 Nov; 25(6 Suppl):651-4. PubMed ID: 5958695
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.